Introduction {#S0001}
============

Fabry disease is a progressive, multisystem disease in which nephropathy and cardiomyopathy are frequent and major complications that can lead to premature death.[@CIT0001]--[@CIT0004] The wide variation in phenotypic presentation among patients with Fabry disease may favor misdiagnosis and delay the correct diagnosis and thus treatment.[@CIT0005],[@CIT0006] Enzyme replacement therapy (ERT) has not been shown to prevent further progression if initiated during an advanced stage of the disease.[@CIT0007],[@CIT0008] Furthermore, evidence-based recommendations promote starting ERT early in the disease course for the greatest therapeutic benefit.[@CIT0009]

The Fabry Outcome Survey (FOS), sponsored by Shire, a Takeda company (Zurich, Switzerland), is an international disease registry that has been collecting longitudinal data since 2001 on patients with a confirmed diagnosis of Fabry disease. Until 2016, patients either untreated or treated with agalsidase alfa were eligible to participate in the registry. Protocol amendment 4 (dated June 29, 2016) allowed any patients with Fabry disease, regardless of treatment (ie, no treatment or any approved Fabry treatment), to be enrolled. The present analysis included only patients who received ERT with agalsidase alfa. To determine the impact of starting ERT early in the course of Fabry disease, this study evaluated renal and cardiac outcomes up to 10 years after ERT initiation in male patients registered in FOS who started ERT at ≤18 years, \>18 and ≤30 years, and \>30 years of age.

Patients and Methods {#S0002}
====================

This was a retrospective study of data from male patients registered in FOS (data extracted August 2018; ClinicalTrials.gov identifier NCT03289065). FOS was approved by the ethics institutional review boards of participating centers ([[Supplemental File](https://www.dovepress.com/get_supplementary_file.php?f=249433.docx)]{.ul}). All participants or their caregivers gave written informed consent. Patients were stratified into three cohorts according to age at initiation of ERT with agalsidase alfa: ≤18 years of age (cohort 1; child), \>18 and ≤30 years of age (cohort 2; young adult), and \>30 years of age (cohort 3; adult). Baseline demographic and clinical characteristics were recorded, including race; age at symptom onset, diagnosis, and ERT initiation; ERT duration; Fabry Outcome Survey-Mainz Severity Score Index (FOS-MSSI) results; estimated glomerular filtration rate (eGFR); proteinuria levels; and left ventricular mass indexed to height (LVMI).

The FOS-MSSI is a scoring index used to measure Fabry disease intensity. It consists of general, neurologic, cardiovascular, and renal components, which are combined to calculate the total MSSI score. Scores \<20 are considered mild, 20--40 moderate, and \>40 severe.[@CIT0010] Clinical judgment about the score must take the age of the patient into account. Renal and cardiac outcomes were analyzed from baseline (defined as within a window of --6 to +3 months around ERT initiation) up to 10 years after ERT initiation. Calculation of eGFR was made using the Counahan-Barratt equation in patients \<18 years of age and the Chronic Kidney Disease Epidemiology Collaboration equation in patients ≥18 years of age. Decreased eGFR was defined as \<90 mL/min/1.73 m^2^ and was used as a measure of reduced renal function.[@CIT0011] Proteinuria was defined as a protein excretion rate of ≥150 mg/day.[@CIT0012] Increased LVMI was considered as values \>50 g/m^2.7^ and was used as a measure of left ventricular hypertrophy (LVH).[@CIT0013]

Statistical Analysis {#S0002-S2001}
--------------------

The baseline demographic and clinical characteristics were compared among the three study cohorts using analysis of variance (ANOVA), which constituted the most appropriate statistical method for comparing means because it assesses the relative size of variance when more than two groups are being tested. The null hypothesis for an ANOVA is that there is no significant difference among the groups, whereas the alternative hypothesis assumes that there is at least one significant difference among the groups. An assumption of normality was assessed in the current study with the Shapiro--Wilk test, and the Tukey's method was used for the *post-hoc* test.

Mixed-effects linear regression analysis was used to estimate mean values for renal and cardiac outcomes for the overall follow-up period within and between cohorts and, subsequently,mean annual changes within each cohort. An unstructured covariance (patient level) with the fixed effect of age at ERT initiation (cohorts 1--3,as listed earlier) and the random effect of patients and time were implemented in the models. Restricted maximum likelihood estimation was used to fit the models. *P* values were calculated using the Wald test. To be included in the mixed-effects linear regression analysis, patients were required to have (1) a minimum of 3 years of receiving ERT,(2) nonmissing baseline data,(3) a minimum of 3 years of postbaseline data,(4) a minimum of three measurements, and (5) no renal dialysis and/or transplant prior to ERT initiation. For patients with renal dialysis and/or transplant at any time over the course of follow-up,data were deleted after the timing of renal dialysis and/or transplant. Data up to a maximum of 10 years after ERT initiation were used.

The level of statistical significance was set at 0.05. All analyses were performed using SAS (SAS software version 9.4).

Results {#S0003}
=======

Baseline Characteristics {#S0003-S2001}
------------------------

A total of 560 male patients registered in FOS received ERT with agalsidase alfa and were included in this study. There were 151 (27.0%) patients in cohort 1, 155 (27.7%) patients in cohort 2, and 254 (45.4%) patients in cohort 3 ([Table 1](#T0001){ref-type="table"}). Median (range) age at symptom onset was lower in cohort 1 (7.5 \[0.0--16.0\] years) than in cohort 2 (8.0 \[0.0--17.0\] years) or cohort 3 (9.0 \[0.0--17.0\] years; *P* = 0.017). Age at diagnosis was higher in each successive age group and ranged from a median (range) of 11.0 (0.0--18.0) years in cohort 1 to 31.0 (0.0--69.0) years in cohort 3. Mean ± SD duration of ERT for cohorts 1, 2, and 3 was 6.3 ± 4.3, 8.6 ± 4.9, and 7.9 ± 4.9 years, respectively. Mean ± SD FOS-MSSI scores at baseline increased with age in each successive cohort, from 9.8 ± 7.2 in cohort 1 to 24.7 ± 11.4 in cohort 3. Mean ± SD eGFR for cohorts 1 and 2 was 113.8 ± 26.9 and 118.3 ± 20.0 mL/min/1.73 m^2^, respectively. Mean ± SD proteinuria for cohorts 1 and 2 was 120.6 ± 239.3 and 295.2 ± 476.6 mg/day, respectively. Additionally, LVMI for cohorts 1 and 2 was 36.7 ± 7.9 and 40.4 ± 11.0 g/m^2.7^, respectively. Cohort 3, comprising the oldest patients, showed the lowest baseline mean ± SD value for eGFR (87.1 ± 29.0 mL/min/1.73 m^2^) and highest baseline mean ± SD values for proteinuria (801.9 ± 952.6 mg/day) and LVMI (56.7 ± 16.0 g/m^2.7^) among the three cohorts.Table 1Demographic and Clinical Characteristics at Baseline in Male Patients with Fabry Disease According to Age at ERT InitiationCharacteristicsCohort 1\
(≤18 Years)\
n = 151Cohort 2\
(\>18 and ≤30 Years)\
n = 155Cohort 3\
(\>30 Years)\
n = 254Total\
N = 560*P* value^a^Race\<0.001 n148155252555 White, n (%)95 (64.2)132 (85.2)213 (84.5)440 (79.3) Black/African American, n (%)1 (0.7)0 (0.0)0 (0.0)1 (0.2) Asian, n (%)49 (33.1)16 (10.3)34 (13.5)99 (17.8) Other, n (%)3 (2.0)7 (4.5)5 (2.0)15 (2.7)Age at symptom onset, y0.017 n112155254521 Mean (SD)7.6 (3.7)8.5 (4.4)8.9 (3.7)8.5 (3.9) Median (Q1, Q3)7.5 (5.0, 10.0)8.0 (5.0, 12.0)9.0 (6.0, 12.0)8.0 (6.0, 11.0) Range0.0--16.00.0--17.00.0--17.00.0--17.0Age at diagnosis, y\<0.001 n146153252551 Mean (SD)10.4 (4.6)17.8 (6.7)29.3 (13.9)21.1 (13.0) Median (Q1, Q3)11.0 (8.0, 14.0)18.0 (14.0, 23.0)31.0 (17.0, 39.0)17.0 (11.0, 30.0) Range0.0--18.00.0--28.00.0--69.00.0--69.0Age at ERT initiation, y\<0.001 n151155254560 Mean (SD)13.0 (3.8)24.1 (3.4)41.6 (8.2)29.1 (13.7) Median (Q1, Q3)13.7 (10.9, 16.1)24.5 (21.2, 26.9)40.3 (34.9, 48.2)27.7 (17.4, 39.4) Range2.5--18.018.0--29.930.0--69.22.5--69.2ERT duration, y\<0.001 n151155254560 Mean (SD)6.3 (4.3)8.6 (4.9)7.9 (4.9)7.6 (4.8) Median (Q1, Q3)5.5 (2.9, 9.4)8.4 (4.0, 12.4)7.0 (3.8, 12.2)7.1 (3.6, 11.7) Range0.0--16.30.0--17.10.0--18.10.0--18.1FOS-MSSI n145152250547\<0.001 Mean (SD)9.8 (7.2)15.1 (8.5)24.7 (11.4)18.1 (11.6) Median (Q1, Q3)8.0 (5.0, 12.5)13.5 (8.3, 21.5)23.5 (16.5, 33.5)16.0 (8.5, 25.5) Range0.0--35.00.0--39.51.0--52.50.0--52.5Used at least one ACE inhibitor n151155254560 Yes, n (%)20 (13.2)50 (32.3)145 (57.1)215 (38.4) No, n (%)131 (86.8)105 (67.7)109 (42.9)345 (61.6)Systolic blood pressure, mmHg\<0.001 n9190155336 Mean (SD)111.6 (14.3)120.1 (13.0)125.2 (16.4)120.1 (16.0) Median (Q1, Q3)110.0 (104.0, 122.0)120.0 (110.0, 129.0)124.0 (115.0, 134.0)120.0 (110.0, 130.0) Range74.0--143.097.0--155.087.0--174.074.0--174.0Diastolic blood pressure, mmHg\<0.001 n9190154335 Mean (SD)63.8 (10.8)71.4 (9.6)75.3 (11.5)71.1 (11.8) Median (Q1, Q3)63.0 (59.0, 70.0)70.0 (64.0, 80.0)74.0 (70.0, 80.0)70.0 (63.0, 80.0) Range40.0--100.047.0--98.050.0--110.040.0--110.0eGFR, mL/min/1.73 m^2b,c^\<0.001 n88109150347 Mean (SD)113.8 (26.9)118.3 (20.0)87.1 (29.0)103.7 (29.7) Median (Q1, Q3)112.4 (96.5, 133.2)120.9 (109.9, 129.6)93.1 (62.7, 110.7)109.1 (85.7, 123.3) Range48.9--171.135.6--163.423.2--145.223.2--171.1Proteinuria, mg/day^d^\<0.001 n6273116251 Mean (SD)120.6 (239.3)295.2 (476.6)801.9 (952.6)486.3 (766.1) Median (Q1, Q3)88.6 (27.0, 142.4)140.0 (70.0, 220.0)440.0 (200.0, 1002.5)180.0 (96.0, 540.0) Range0.0--1870.00.0--2450.00.0--4900.00.0--4900.0LVMI, g/m^2.7e^\<0.001 n445674174 Mean (SD)36.7 (7.9)40.4 (11.0)56.7 (16.0)46.4 (15.6) Median (Q1, Q3)34.9 (32.3, 38.4)37.9 (33.1, 45.8)55.6 (45.8, 67.9)43.2 (34.3, 55.5) Range22.0--61.019.2--76.925.8--96.619.2--96.6[^1][^2]

Totals of 15 (17.0%; n = 88), 11 (10.1%; n = 109), and 70 (46.7%; n = 150) patients in cohorts 1, 2, and 3, respectively, had pathological eGFR (\<90 mL/min/1.73 m^2^) at baseline; whereas 13 (21.0%; n = 62), 35 (47.9%; n = 73), and 94 (81.0%; n = 116) patients in cohorts 1, 2, and 3, respectively, had pathological proteinuria (≥150 mg/day) at baseline. Totals of 3 (6.8%; n = 44), 9 (16.1%; n = 56), and 48 (64.9%; n = 74) patients in cohorts 1, 2, and 3, respectively, had pathological LVMI (\>50 g/m^2.7^) at baseline.

Follow-up for ERT {#S0003-S2002}
-----------------

In a comparison of the cohorts, the overall mean values for eGFR and proteinuria did not significantly differ between patients in cohorts 1 and 2 during the follow-up period for ERT, whereas some significant differences were found for LVMI ([Table 2](#T0002){ref-type="table"}). However, a comparison of patients in cohorts 1 and 3 showed significant differences in overall mean values for eGFR (117.9 vs 79.9 mL/min/1.73 m^2^, respectively), proteinuria (210.7 vs 819.5 mg/day, respectively), and LVMI (33.6 vs 55.5 g/m^2.7^, respectively; *P* \< 0.001 for each). A comparison of patients in cohorts 2 and 3 also showed significant differences in overall mean values for eGFR (114.1 vs 79.9 mL/min/1.73 m^2^, respectively), proteinuria (395.5 vs 819.5 mg/day, respectively), and LVMI (40.0 vs 55.5 g/m^2.7^, respectively; *P* \< 0.001 for each).Table 2Mixed-Effects Linear Regression Analysis^a^ Showing Mean Values of eGFR, Proteinuria, and LVMI for the Overall Follow-Up Period in Each Study Cohort, with a Comparison Between the CohortsParameterCohort 1 (≤18 Years)Cohort 2 (\>18 and ≤30 Years)Cohort 3 (\>30 Years)Cohort 1 vs Cohort 2Cohort 1 vs Cohort 3Cohort 2 vs Cohort 3n^b^Mean (95% CI)n^b^Mean (95% CI)n^b^Mean (95% CI)Difference (95% CI)*P* Value^c^Difference (95% CI)*P* Value^c^Difference (95% CI)*P* Value^c^eGFR, mL/min/1.73 m^2^55117.9 (111.8 to 124.1)84114.1 (109.2 to 119.1)11779.9 (75.7 to 84.1)3.8 (--4.1 to 11.7)0.34738.1 (30.6 to 45.5)\<0.00134.3 (27.8 to 40.8)\<0.001Proteinuria, mg/day42210.7 (1.1 to 420.3)45395.5 (194.4 to 596.6)91819.5 (678.4 to 960.7)--184.8 (--475.3 to 105.7)0.212--608.8 (--861.5 to --356.1)\<0.001--424.0 (--669.7 to --178.3)\<0.001LVMI, g/m^2.7^3133.6 (29.5 to 37.7)3840.0 (36.3 to 43.7)5655.5 (52.4 to 58.5)--6.4 (--11.9 to --0.8)0.024--21.9 (--27.0 to --16.8)\<0.001--15.5 (--20.3 to --10.7)\<0.001[^3][^4]

For patients in cohort 1, no significant annual changes in eGFR, proteinuria, or LVMI were observed throughout the follow-up period ([Table 3](#T0003){ref-type="table"}). For patients in cohort 2, although proteinuria and LVMI remained stable, eGFR showed a significant annual decline over the follow-up period (slope, --1.12 mL/min/1.73 m^2^ \[95% confidence interval {CI}, --1.77 to --0.47\]; *P* \< 0.001). For patients in cohort 3, a significant annual deterioration over the follow-up period was shown for eGFR (slope, --2.60 mL/min/1.73 m^2^ \[95% CI, --3.16 to --2.04\]; *P* \< 0.001), proteinuria (slope, +34.10 mg/day \[95% CI, 18.48--49.71\]; *P* \< 0.001), and LVMI (slope, +0.59 g/m^2.7^ \[95% CI, 0.23--0.95\]; *P* = 0.001). [Figures 1](#F0001){ref-type="fig"}--[3](#F0003){ref-type="fig"} illustrate the estimated annual rates of change over the follow-up period for each cohort by parameter, showing that the patients in cohort 3 had worsening rates of change during follow-up for eGFR, proteinuria, and LVMI in comparison with cohorts 1 and 2.Table 3Mixed-Effects Linear Regression Analysis^a^ Showing Intercepts (Mean Values at Baseline) and Slopes (Mean Annual Rates of Change) for eGFR, Proteinuria, and LVMI for the Overall Follow-Up PeriodParameterCohort 1 (≤18 Years)Cohort 2 (\>18 and ≤30 Years)Cohort 3 (\>30 Years)n^b^Intercept (95% CI)Slope (95% CI)*P* Value^c^n^b^Intercept (95% CI)Slope (95% CI)*P* Value^c^n^b^Intercept (95% CI)Slope (95% CI)*P* Value^c^eGFR, mL/min/1.73 m^2^55116.2 (110.3 to 122.0)0.44 (--0.42 to 1.30)0.31384118.6 (113.8 to 123.3)--1.12 (--1.77 to --0.47)\<0.00111790.2 (86.2 to 94.2)--2.60 (--3.16 to --2.04)\<0.001Proteinuria, mg/day42164.8 (--25.9 to 355.6)12.06 (--13.65 to 37.76)0.35845339.7 (155.5 to 523.8)14.68 (--7.18 to 36.54)0.18891689.8 (561.1 to 818.5)34.10 (18.48 to 49.71)\<0.001LVMI, g/m^2.7^3134.2 (30.2 to 38.2)--0.17 (--0.66 to 0.31)0.4903839.5 (35.9 to 43.2)0.11 (--0.29 to 0.52)0.5885653.3 (50.3 to 56.3)0.59 (0.23 to 0.95)0.001[^5][^6] Figure 1Estimated regression lines for estimated glomerular filtration rate (eGFR) values over time according to age at enzyme replacement therapy (ERT) initiation.Figure 2Estimated regression lines for proteinuria values over time according to age at enzyme replacement therapy (ERT) initiation.Figure 3Estimated regression lines for left ventricular mass indexed to height (LVMI) values over time according to age at enzyme replacement therapy (ERT) initiation.

Discussion {#S0004}
==========

The three different age cohorts included in this analysis effectively represent populations at different stages of disease progression, as expected and as reflected by the FOS-MSSI scores and clinical symptoms.

We observed that individuals with systemic Fabry disease treated with ERT in childhood or early adulthood (cohorts 1 and 2) exhibited a stable eGFR slope or a slight decline in eGFR slope, respectively, and no changes in proteinuria slope during the course of the follow-up period. The slopes for eGFR and proteinuria were much more pronounced in cohort 3 compared to cohorts 1 and 2.

Breunig et al reported a worse outcome and greater likelihood of reaching renal and cardiovascular end points in male and female patients treated with agalsidase alfa who had more severe renal involvement at baseline.[@CIT0014] Germain et al also reported an increased likelihood of renal disease progression in patients treated with agalsidase beta who already had higher renal impairment at baseline, compared with patients who did not.[@CIT0015] A 10-year outcome study that included male and female patients receiving agalsidase beta ERT found greater benefit from initiating ERT in younger patients with less severe renal disease than in older patients with more severe renal disease, in whom disease progression was observed.[@CIT0007] In contrast, Beck et al reported a benefit of agalsidase alfa ERT even in male patients with the lowest eGFR values at baseline, as indicated by a slower decline in renal disease progression compared with untreated patients.[@CIT0016]

Owing to the lack of a control group of untreated patients, we cannot say with certainty to what extent the favorable slopes in cohorts 1 and 2 may depend on treatment. However, the effect of ERT on the natural progression of the disease is easily recognized if we compare the aforementioned findings with those of untreated patients. In a 2017 article by Arends et al, the natural history of Fabry disease was studied in 596 patients from three European centers; 129 patients with available data were male and had classical Fabry disease.[@CIT0017] The slope of linear regression reported for eGFR in these patients shows a decline starting from 20 years of age; in comparison, the slopes of cohorts 1 and 2 observed in the present study were fairly stable over the course of the follow-up period. Our data analysis also indicated a numerically statistically significant decline found with cohort 2 (eGFR slope --1.12), which is consistent with the natural yearly decline of eGFR found in healthy individuals (--0.82 ± 0.22 for those aged 20--30 years and --1.15 ± 0.12 mL/min/1.73 m^2^ per year for those aged \>50 years).[@CIT0019] The slope for cohort 3, however, was more similar to that shown by Arends et al for patients of approximately the same age.[@CIT0017] Schiffmann et al reported the natural progression of chronic kidney disease in untreated adult patients with Fabry disease and showed that male patients with eGFR ≥60 mL/min/1.73 m^2^ and a mean age of 27.3 years had a rate of eGFR decline of 2.93 mL/min/1.73 m^2^ per year.[@CIT0018] This group of male patients was of approximately the same age as this study's cohort 2, in which patients showed a much slower annual decline of eGFR with a slope of --1.12 per year. Schiffman et al also reported that in a group of patients who were of comparable age to this study's cohort 3 and had progressed to end-stage renal disease, the eGFR slope was --3.85; this contrasts with the eGFR slope of --2.60 observed in cohort 3 in the present study. Schiffman et al also reported in a subgroup of untreated patients with higher proteinuria at baseline a decline in eGFR of --6.9.

The current analysis found that in patients with the most severe renal disease, the highest proteinuria was observed at baseline and was consistently high throughout the follow-up period. In agreement with a previously reported age at onset of proteinuria of 34 ± 10 years,[@CIT0001] significant increases in annual rates of proteinuria were found only in patients in cohort 3, whereas in patients who started ERT in childhood or early adulthood, no annual changes of proteinuria were identified. Kampmann et al reported a significant increase in urinary protein levels after 10 years in male patients who had proteinuria before agalsidase alfa ERT initiation, whereas no significant changes were seen in patients without baseline proteinuria.[@CIT0020]

LVMI did not progress in cohorts 1 and 2 over the course of the follow-up period. Although in patients younger than 30 years of age the prevalence of LVMI is known to be low,[@CIT0021] it is possible that ERT contributed to stabilizing LVMI in cohorts 1 and 2. In cohort 3, there was evidence of significant deterioration of LVMI over the course of the follow-up period. Again, owing to the lack of an untreated control group, it is difficult to determine the effect of ERT. However, the slope representing the linear regression curve of LVMI in untreated patients shown by Arends et al[@CIT0017] appears to be very different from that shown for cohorts 1 and 2 of this analysis in patients of approximately the same age. Age at onset of LVH in untreated patients has been reported to be in the fourth to fifth decade for male patients and the sixth decade for female patients;[@CIT0002],[@CIT0004] however, Wu et al reported LVH even in female patients \<20 years of age.[@CIT0022] Weidemann et al demonstrated progression of cardiac and renal disease in patients with advanced Fabry disease, despite treatment with agalsidase alfa or beta.[@CIT0008] Germain et al reported that initiating agalsidase beta ERT in male patients ≥40 years of age was associated with greater LVH progression compared with male patients ≤30 years of age.[@CIT0023] Kampmann et al found a significant reduction of LVMI in male patients with LVH at baseline after 1 year of ERT with agalsidase alfa, which was sustained over 10 years.[@CIT0020]

There are limitations to these analyses to be considered. FOS is an observational registry and lacks a control group for intraregistry data comparisons. Because patients are not randomly enrolled in disease registries, selection bias in favor of those individuals with worse disease may have been introduced to the data evaluated in this study. Patient numbers in the three cohorts were relatively small, and some data were unavailable for inclusion in the analyses, as is often the case in rare disease registries. All findings should be interpreted with caution owing to the large amount of missing values, especially in cohort 3. Because the analysis period was limited to a maximum of 10 years after ERT initiation, some male patients in cohort 1 were still young and at an age where the effect of the disease on the heart and kidney is likely to be mild, even if untreated. Lastly, although further analysis of study participants according to phenotype/mutation would be informative, it was not practically feasible due to a limited availability of genetic data.

The current analysis shows that ERT is associated with attenuation of progressive Fabry disease--related renal and cardiac disease in patients who started treatment between 18 and 30 years of age (cohort 2). Our data reasonably suggest that this effect could be even more pronounced in cohort 1 (patients starting ERT before 18 years of age), but, owing to the well-known evolution of Fabry disease in the first 3 decades of life and to the lack of a control group, we cannot assert the finding. Older patients are generally expected to have a worse prognosis in Fabry disease. It is thus true that cohort 3 included older patients compared to cohort 1 and cohort 2 and may be at a more advanced disease stage, thus reinforcing the idea of early starting treatment to achieve a slowing of disease progression.

Conclusion {#S0005}
==========

In a small cohort of patients with full sets of longitudinal data, the current analysis shows that initiating ERT in childhood and young adulthood was associated with greater attenuation of progressive Fabry disease--related renal and cardiac disease compared with initiating ERT in later adulthood. These results add to and support the growing body of evidence indicating that greater clinical benefits may be obtained the earlier ERT is initiated.
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[^1]: **Notes:** ^a^*P* value, comparing the mean values across the three cohorts, derived from analysis of variance; ^b^eGFR values were restricted to between \>15 and ≤180 mL/min/1.73 m^2^, values outside this range were considered as missing; ^c^eGFR was calculated using the Counahan-Barratt equation in patients \<18 years of age and the Chronic Kidney Disease Epidemiology Collaboration equation in patients ≥18 years of age; ^d^proteinuria values were restricted to between ≥0 and ≤5000 mg/day, values outside this range were considered as missing; ^e^LVMI values were restricted to between \>10 and ≤100 g/m^2.7^, values outside this range were considered as missing.

[^2]: **Abbreviations:** ACE, angiotensin-converting enzyme; CI, confidence interval; eGFR, estimated glomerular filtration rate; ERT, enzyme replacement therapy; FOS-MSSI, Fabry Outcome Survey-Mainz Severity Score Index; LVMI, left ventricular mass indexed to height; Q, quartile; SD, standard deviation.

[^3]: **Notes:** ^a^Analysis performed only in patients with (1) a minimum of 3 years of receiving ERT, (2) nonmissing baseline data, (3) a minimum of 3 years of postbaseline data, (4) a minimum of three measurements, and (5) no renal dialysis and/or transplant prior to ERT initiation; ^b^numbers at baseline; ^c^P value (calculated using the Wald test) comparing overall mean values between cohorts.

[^4]: **Abbreviations:** CI, confidence interval; eGFR, estimated glomerular filtration rate; LVMI, left ventricular mass indexed to height.

[^5]: **Notes:** ^a^Analysis performed only in patients with (1) a minimum of 3 years of receiving ERT, (2) nonmissing baseline data, (3) a minimum of 3 years of postbaseline data, (4) a minimum of three measurements, and (5) no renal dialysis and/or transplant prior to ERT initiation; ^b^numbers at baseline; ^c^P value (calculated using the Wald test) evaluating significance in the annual rate of change within each cohort.

[^6]: **Abbreviations:** CI, confidence interval; eGFR, estimated glomerular filtration rate; LVMI, left ventricular mass indexed to height.
